Search

Your search keyword '"Bilo, B."' showing total 13 results
Start Over Author "Bilo, B." Database OpenAIRE
13 results on '"Bilo, B."'

2. Allergy immunotherapy across the life cycle to promote active and healthy ageing : from research to policies

Author

Calderon, M. A., Demoly, P., Casale, T., Akdis, C. A., Bachert, C., Bewick, M., Bilo, B. M., Bohle, B., Bonini, S., Bush, A., Caimmi, D. P., Canonica, G. W., Cardona, V., Chiriac, A. M., Cox, L., Custovic, A., De Blay, F., Devillier, P., Didier, A., Di Lorenzo, G., Du Toit, G., Durham, S. R., Eng, P., Fiocchi, A., Fox, A. T., van Wijk, R. Gerth, Gomez, R. M., Haahtela, Tari Markku Kallevi, Halken, S., Hellings, P. W., Jacobsen, L., Just, J., Tanno, L. K., Kleine-Tebbe, J., Klimek, L., Knol, E. F., Kuna, P., Larenas-Linnemann, D. E., Linneberg, A., Matricardi, M., Malling, H. J., Moesges, R., Mullol, J., Muraro, A., Papadopoulos, N., Passalacqua, G., Pastorello, E., Pfaar, O., Price, D., Rodriguez del Rio, P., Rueff, R., Samolinski, B., Scadding, G. K., Senti, G., Shamji, M. H., Sheikh, A., Sisul, J. C., Sole, D., Sturm, G. J., Tabar, A., Van Ree, R., Ventura, M. T., Vidal, C., Varga, E. M., Worm, M., Zuberbier, T., Bousquet, J., Clinicum, and Department of Dermatology, Allergology and Venereology

Subjects
EIP on AHA, EAACI POSITION PAPER, RUSH IMMUNOTHERAPY, GRASS-POLLEN ALLERGY, INTERNATIONAL CONSENSUS, EUROPEAN INNOVATION PARTNERSHIP, NATIONAL DATABASES, ORAL IMMUNOTHERAPY, Asthma, Ageing, AIRWAYS ICPs, SUBLINGUAL IMMUNOTHERAPY, PRECISION MEDICINE, IMMUNOLOGY/PRACTALL CONSENSUS REPORT, 3121 General medicine, internal medicine and other clinical medicine, Allergen immunotherapy, Rhinitis
Abstract

Allergic diseases often occur early in life and persist throughout life. This life-course perspective should be considered in allergen immunotherapy. In particular it is essential to understand whether this al treatment may be used in old age adults. The current paper was developed by a working group of AIRWAYS integrated care pathways for airways diseases, the model of chronic respiratory diseases of the European Innovation Partnership on active and healthy ageing (DG CONNECT and DG Sante). It considered (1) the political background, (2) the rationale for allergen immunotherapy across the life cycle, (3) the unmet needs for the treatment, in particular in preschool children and old age adults, (4) the strategic framework and the practical approach to synergize current initiatives in allergen immunotherapy, its mechanisms and the concept of active and healthy ageing.

Published
2016

3. Drug allergy passport and other documentation for patients with drug hypersensitivity – An ENDA/EAACI Drug Allergy Interest Group Position Paper

Author

Brockow, K. Aberer, W. Atanaskovic-Markovic, M. Bavbek, S. Bircher, A. Bilo, B. Blanca, M. Bonadonna, P. Burbach, G. Calogiuri, G. Caruso, C. Celik, G. Cernadas, J. Chiriac, A. Demoly, P. Oude Elberink, J.N.G. Fernandez, J. Gomes, E. Garvey, L.H. Gooi, J. Gotua, M. Grosber, M. Kauppi, P. Kvedariene, V. Laguna, J.J. Makowska, J.S. Mosbech, H. Nakonechna, A. Papadopolous, N.G. Ring, J. Romano, A. Rockmann, H. Sargur, R. Sedlackova, L. Sigurdardottir, S. Schnyder, B. Storaas, T. Torres, M. Zidarn, M. Terreehorst, I.

Abstract

The strongest and best-documented risk factor for drug hypersensitivity (DH) is the history of a previous reaction. Accidental exposures to drugs may lead to severe or even fatal reactions in sensitized patients. Preventable prescription errors are common. They are often due to inadequate medical history or poor risk assessment of recurrence of drug reaction. Proper documentation is essential information for the doctor to make sound therapeutic decision. The European Network on Drug Allergy and Drug Allergy Interest Group of the European Academy of Allergy and Clinical Immunology have formed a task force and developed a drug allergy passport as well as general guidelines of drug allergy documentation. A drug allergy passport, a drug allergy alert card, a certificate, and a discharge letter after medical evaluation are adequate means to document DH in a patient. They are to be handed to the patient who is advised to carry the documentation at all times especially when away from home. A drug allergy passport should at least contain information on the culprit drug(s) including international nonproprietary name, clinical manifestations including severity, diagnostic measures, potential cross-reactivity, alternative drugs to prescribe, and where more detailed information can be obtained from the issuer. It should be given to patients only after full allergy workup. In the future, electronic prescription systems with alert functions will become more common and should include the same information as in paper-based documentation. © 2016 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd

Published
2016

4. The Drug Ambassador Project - The diversity of diagnostic procedures for drug allergy around Europe

Author

Gomes, Eva Rebelo, Pichler, Werner J., Demoly, Pascal, Aberer, Werner, Frew, Anthony J., de Weck, Alain, Ballmer Weber, B. K., Barbaud, A., Bilo, B., Bircher, A., Birnbaum, J., Blanca, M., Blömecke, B., Brockow, K., Campi, P., Dzviga, C., Drouet, M., Eberlein König, B., Fernandez, J., Fuchs, T., Guéant, J. L., Gutgesell, C., Hertl, M., Kanny, G., Kapp, A., Kidon, M., Kowalski, M., Merk, H., Moneret Vaultrin, A. D., Pascual Marcos, C., Przybilla, B., Ring, J., Romano, A., Rueff, F., Sabbah, A., Sainte Laudy, J., Sanz, M., Tas, E., Torres, M. J., Vervloet, D., Wedi, B., Wüthrich, B., MARONE, GIANNI, Gomes, Eva Rebelo, Pichler, Werner J., Demoly, Pascal, Aberer, Werner, Frew, Anthony J., de Weck, Alain, Ballmer Weber, B. K., Barbaud, A., Bilo, B., Bircher, A., Birnbaum, J., Blanca, M., Blömecke, B., Brockow, K., Campi, P., Dzviga, C., Drouet, M., Eberlein König, B., Fernandez, J., Fuchs, T., Guéant, J. L., Gutgesell, C., Hertl, M., Kanny, G., Kapp, A., Kidon, M., Kowalski, M., Marone, Gianni, Merk, H., Moneret Vaultrin, A. D., Pascual Marcos, C., Przybilla, B., Ring, J., Romano, A., Rueff, F., Sabbah, A., Sainte Laudy, J., Sanz, M., Tas, E., Torres, M. J., Vervloet, D., Wedi, B., and Wüthrich, B.

Subjects
Immunology and Allergy, Standardization, Diagnosi, Drug hypersensitivity
Published
2005

5. Diagnosis of immediate allergic reactions to beta-lactam antibiotics

Author

Torres, Maria J, Blanca, M., Fernandez, J., Romano, A., De Weck, A., Aberer, W., Brockow, K., Pichler, Werner J., Demoly, Pascal, Ballmer Weber, B. K., Barbaud, A., Bilo, B., Bircher, A., Birmbaum, J., Blömecke, B., Campi, P., Dzviga, C., Drouet, M., Eberlein König, B., Frew, T., Fuchs, T., Guéant, J. L., Gutgesell, C., Hertl, M., Kanny, G., Kapp, A., Kidon, M., Kowalski, M., Merk, H., Moneret Vautrin, A. D., Pascual Marcos, C., Przybilla, B., Rebelo Gomes, E., Ring, J., Rueff, F., Sabbah, A., Sainte Laudy, J., Sanz, M., Tas, E., Vervloet, D., Wedi, B., Wüthrich, B., MARONE, GIANNI, Torres, Maria J, Blanca, M., Fernandez, J., Romano, A., De Weck, A., Aberer, W., Brockow, K., Pichler, Werner J., Demoly, Pascal, Ballmer Weber, B. K., Barbaud, A., Bilo, B., Bircher, A., Birmbaum, J., Blömecke, B., Campi, P., Dzviga, C., Drouet, M., Eberlein König, B., Frew, T., Fuchs, T., Guéant, J. L., Gutgesell, C., Hertl, M., Kanny, G., Kapp, A., Kidon, M., Kowalski, M., Marone, Gianni, Merk, H., Moneret Vautrin, A. D., Pascual Marcos, C., Przybilla, B., Rebelo Gomes, E., Ring, J., Rueff, F., Sabbah, A., Sainte Laudy, J., Sanz, M., Tas, E., Vervloet, D., Wedi, B., and Wüthrich, B.

Subjects
medicine.medical_specialty, Allergy, Clinical immunology, Immunology, beta-Lactams, Beta-lactam, Drug Hypersensitivity, chemistry.chemical_compound, Risk Factors, Clavulanic acid, medicine, Immunology and Allergy, Humans, Drug reaction, Child, Skin Tests, business.industry, medicine.disease, Dermatology, Anti-Bacterial Agents, chemistry, Interest group, business, Algorithms, medicine.drug, Beta lactam antibiotics
Abstract

Allergic reactions to betalactams are the most common cause of adverse drug reactions mediated by specific immunological mechanisms. Reactions may be induced by all betalactams currently available, ranging from benzylpenicillin (BP) to other more recently introduced betalactams, such as aztreonam or the related betalactamase-inhibitor clavulanic acid (Fig. 1) (1–5). Although the production process of betalactams has improved over the years, the number of reactions has not decreased, M. J. Torres, M. Blanca, J. Fernandez, A. Romano, A. de Weck, W. Aberer, K. Brockow, W. J. Pichler, P. Demoly for ENDA, and the EAACI interest group on drug hypersensitivity Allergy Service, Carlos Haya Hospital, Malaga, Spain; Allergy Service, University La Paz, Madrid, Spain; Allergy Section, Dept. Clin. Med., UMH, Elche, Spain; Allergy Service, Catholic University of Rome, Italy; Fondation Gerimmun, Beaumont 18, CH1700, Fribourg, Switzerland; Department of Environmental Dermatology, Graz, Austria; Klinik und Poliklinik f5r Dermatologie und Allergologie, Muenchen, Germany; Clinic for Rheumatology and Clinical Immunology/Allergy, Inselspital, Bern, Switzerland; Maladies Respiratoires-INSERM U454, Hopital Arnaud de Villeneuve, Montpellier, France

Published
2003

6. EAACI: a European declaration on immunotherapy. Design the future of allergen specific immunotherapy

Author

Calderon, MA, Demoly, P, Gerth van Wijk, Roy, Bousquet, J, Sheikh, A (Aziz), Frew, A, Scadding, GK, Bachert, C, Malling, H-J, Valenta, R, Bilo, B, Nieto, A, Akdis, CA, Just, J, Vidal, C, Varga, EM, Alvarez-Cuesta, E, Bohle, E, Bufe, A, Canonica, GW, Cardona, V, Dahl, R, Didier, A, Durham, SR, Eng, P, Fernandez-Rivas, M, Jacobsen, L, Jutel, M, Klein-Tebbe, J, Klimek, L, Lotvall, J, Moreno, C, Mosges, R, Muraro, A, Niggemann, B, Pajno, G, Passalacqua, G, Pfaar, O, Rak, S, Senna, GE, Senti, G, Valovirta, E, van Hage, M, Virchow, JC, Wahn, U, Papadopoulos, N, and Internal Medicine

Published
2012

7. Clinical and translational allergy / Research needs in allergy: an EAACI position paper, in collaboration with EFA

Author

Papadopoulos, Nikos G., Agache, I., Bavbek, S., Bilo, B. M., Braido, F., Cardona, V., Custovic, A., Demonchy, J., Demoly, P., Eigenmann, P., Gayraud, J., Grattan, C., Heffler, E., Hellings, P. W., Jutel, M., Knol, E., Lotvall, J., Muraro, A., Poulsen, L. K., Roberts, G., Schmid-Grendelmeier, P., Skevaki, C., Triggiani, M., Vanree, R., Werfel, T., Flood, B., Palkonen, S., Savli, R., Allegri, P., Annesi-Maesano, I., Annunziato, F., Antolin-Amerigo, D., Apfelbacher, C., Blanca, M., Bogacka, E., Bonadonna, P., Bonini, M., Boyman, O., Brockow, K., Burney, P., Buters, J., Butiene, I., Calderon, M., Cardell, L. O., Caubet, J. C., Celenk, S., Cichocka-Jarosz, E., Cingi, C., Couto, M., Dejong, N., Del Giacco, S., Douladiris, N., Fassio, F., Fauquert, J. L., Fernandez, J., Rivas, M. F., Ferrer, M., Flohr, C., Gardner, J., Genuneit, J., Gevaert, P., Groblewska, A., Hamelmann, E., Hoffmann, H. J., Hoffmann-Sommergruber, K., Hovhannisyan, L., Hox, V., Jahnsen, F. L., Kalayci, O., Kalpaklioglu, A. F., Kleine-Tebbe, J., Konstantinou, G., Kurowski, M., Lau, S., Lauener, R., Lauerma, A., Logan, K., Magnan, A., Makowska, J., Makrinioti, H., Mangina, P., Manole, F., Mari, A., Mazon, A., Mills, C., Mingomataj, E., Niggemann, B., Nilsson, G., Ollert, M., O'Mahony, L., O'Neil, S., Pala, G., Papi, A., Passalacqua, G., Perkin, M., Pfaar, O., Pitsios, C., Quirce, S., Raap, U., Raulf-Heimsoth, M., Rhyner, C., Robson-Ansley, P., Alves, R. R., Roje, Z., Rondon, C., Rudzeviciene, O., Rueff, F., Rukhadze, M., Rumi, G., Sackesen, C., Santos, A. F., Santucci, A., Scharf, C., Schmidt-Weber, C., Schnyder, B., Schwarze, J., Senna, G., Sergejeva, S., Seys, S., Siracusa, A., Skypala, I., Sokolowska, M., Spertini, F., Spiewak, R., Sprikkelman, A., Sturm, G., Swoboda, Ines, Terreehorst, I., Toskala, E., Traidl-Hoffmann, C., Venter, C., Vlieg-Boerstra, B., Whitacker, P., Worm, M., Xepapadaki, P., and Akdis, C. A.

Published
2012
Full Text
View/download PDF

9. Reducing the risk of anaphylaxis during anaesthesia: Guidelines for clinical practice

Author

Mertes, P. M., Laxenaire, M. C., Lienhart, A., Aberer, W., Ring, J., Pichler, W. J., Demoly, P., Decroix, G., Dewachter, P., Guéant, J. L., Guilloux, L., Laroche, D., Leynadier, F., Longrois, D., Malinovsky, J. M., Moneret-Vautrin, D. A., Pecquet, C., Pinaud, M., Tréchot, P., Vervloet, D., Wessel, F., Ballmer-Weber, B. K., Barbaud, A., Bilo, B., Birnbaum, J., Bianca, M., Blömecke, B., Brockow, K., Christiansen, C., Weck, A., Dzviga, C., Drouet, M., Eberlein-König, B., Frew, A. T., Fuchs, T., Guéant-Rodriguez, R. M., Gutgesell, C., Hertl, M., Kanny, G., Kapp, A., Kidon, M., Kowalski, M., Marone, G., Merk, H., Pascual-Marcos, C., Przybilla, B., Rebelo-Gomes, E., Rueff, F., Sabbah, A., Sainte Laudy, J., Sanz, M. L., Tas, E., Romano, A., Torres, M. J., Bettina Wedi, Wüthrich, B., Mertes, Paul Michel, Laxenaire, M. C., Lienhart, A., Aberer, W., Ring, J., Pichler, W. J., Demoly, Pascal, Decroix, G., Dewachter, P., Guéant, J. L., Guilloux, L., Laroche, D., Leynadier, F., Longrois, D., Malinovsky, J. M., Moneret Vautrin, D. A., Pecquet, C., Pinaud, M., Tréchot, P., Vervloet, D., Wessel, F., Ballmer Weber, B. K., Barbaud, A., Bilo, B., Birnbaum, J., Bianca, M., Blömecke, B., Brockow, K., Christiansen, C., De Weck, A., Dzviga, C., Drouet, M., Eberlein König, B., Frew, A. T., Fuchs, T., Guéant Rodriguez, R. M., Gutgesell, C., Hertl, M., Kanny, G., Kapp, A., Kidon, M., Kowalski, M., Marone, Gianni, Merk, H., Pascual Marcos, C., Przybilla, B., Rebelo Gomes, E., Rueff, F., Sabbah, A., Sainte Laudy, J., Sanz, M. L., Tas, E., Romano, A., Torres, M. J., Wedi, B., and Wüthrich, B.

Subjects
Anaesthesia, Skin test, Latex, Anaphylaxi, Neuromuscular blocking agent, Hypersensitivity, Tryptase, Immunology and Allergy, IgE, Histamine, Hypnotic

10. Biventricular arrhythmogenic cardiomyopathy: a paradigmatic case

Author

Alice Ghidoni, Federica Dagradi, Camilla Torlasco, Maria Christina Kotta, Barbara Bilo, Lia Crotti, Franco Cecchi, Peter J. Schwartz, Giulia Girardengo, Giovanni Battista Perego, Gianfranco Parati, Miriam Revera, Margherita Calcagnino, Anna Maria Di Blasio, Calcagnino, M, Girardengo, G, Ghidoni, A, Kotta, M, Di Blasio, A, Revera, M, Torlasco, C, Perego, G, Bilo, B, Dagradi, F, Crotti, L, Parati, G, Schwartz, P, and Cecchi, F

Subjects
medicine.medical_specialty, biology, business.industry, Desmoplakin, Cardiomyopathy, lcsh:A, Arrhythmogenic cardiomyopathy, Sudden death, Syncope, Ventricular tachycardia, Cardiac magnetic resonance, Desmoplakin, ARVC, BIO/18 - GENETICA, MED/11 - MALATTIE DELL'APPARATO CARDIOVASCOLARE, medicine.disease, Ventricular tachycardia, Sudden death, Internal medicine, medicine, Cardiology, biology.protein, lcsh:General Works, Cardiac magnetic resonance, business, General Economics, Econometrics and Finance
Abstract

Arrhythmogenic Cardiomyopathy is a complex clinical entity, sometimes difficult to diagnose. Three main different patterns of disease expression characterize clinically this hereditary heart muscle disease: the “classic” right ventricular form (ARVC), the “left dominant” subtype (LDAC), with primary left ventricular involvement, and the “biventricular” variant, defined by parallel involvement of both ventricles. We report on a case of a 51 years old man with a strong family history of juvenile sudden cardiac death of supposed ischaemic origin and personal history of ventricular arrhythmias and supposed myocarditis. We demonstrate how an accurate anamnesis plus correct interpretation of traditional non invasive tests followed by more sophisticate new non invasive tests such as cardiac magnetic resonance and genetic testing allowed to reach the correct diagnosis.

Published
2015

11. Changes in 24 h ambulatory blood pressure and effects of angiotensin II receptor blockade during acute and prolonged high-altitude exposure: a randomized clinical trial

Author

Andrea Giuliano, Grzegorz Bilo, Barbara Bilo, Giuseppe Mancia, Piergiuseppe Agostoni, Alberto Piperno, Antonella Zambon, Francesca Gregorini, Pietro Amedeo Modesti, Andrea Faini, Gianluca Caldara, Miriam Revera, Katarzyna Styczkiewicz, Carolina Lombardi, Gianfranco Parati, Parati, G, Bilo, G, Faini, A, Bilo, B, Revera, M, Giuliano, A, Lombardi, C, Caldara, G, Gregorini, F, Styczkiewicz, K, Zambon, A, Piperno, A, Modesti, P, Agostoni, P, and Mancia, G

Subjects
Adult, Male, Angiotensin receptor, medicine.medical_specialty, Ambulatory blood pressure, Time Factors, Blood Pressure, Benzoates, chemistry.chemical_compound, Double-Blind Method, Internal medicine, Renin–angiotensin system, medicine, High altitude, Humans, Telmisartan, Angiotensin receptor blocker, Hypoxia, malattie cardiovascolari, hypertension, Aldosterone, business.industry, Altitude, Hypoxia (medical), Effects of high altitude on humans, Blood Pressure Monitoring, Ambulatory, Circadian Rhythm, Blood pressure, Endocrinology, chemistry, Benzimidazoles, Female, Ambulatory blood pressure monitoring, medicine.symptom, business, Cardiology and Cardiovascular Medicine, Angiotensin II Type 1 Receptor Blockers, medicine.drug
Abstract

Aim Many hypertensive subjects travel to high altitudes, but little is known on ambulatory blood pressure (ABP) changes and antihypertensive drugs' efficacy under acute and prolonged exposure to hypobaric hypoxia. In particular, the efficacy of angiotensin receptor blockers in this condition is unknown. This may be clinically relevant considering that renin–angiotensin system activity changes at altitude. The HIGHCARE-HIMALAYA study assessed changes in 24 h ABP under acute and prolonged exposure to increasing altitude and blood pressure-lowering efficacy and safety of an angiotensin receptor blockade in this setting. Methods and results Forty-seven healthy, normotensive lowlanders were randomized to telmisartan 80 mg or placebo in a double-blind, parallel group trial. Conventional and Ambulatory BPs were measured at baseline and on treatment: after 8 weeks at sea level, and under acute exposure to 3400 and 5400 m altitude, the latter upon arrival and after 12 days (Mt. Everest base camp). Blood samples were collected for plasma catecholamines, renin, angiotensin, and aldosterone. In both groups, exposure to increasing altitude was associated with: (i) significant progressive increases in conventional and 24 h blood pressure, persisting throughout the exposure to 5400 m; (ii) increased plasma noradrenaline and suppressed renin–angiotensin–aldosterone system. Telmisartan lowered 24 h ABP at the sea level and at 3400 m (between-group difference 4.0 mmHg, 95% CI: 2.2–9.5 mmHg), but not at 5400 m. Conclusion Ambulatory blood pressure increases progressively with increasing altitude, remaining elevated after 3 weeks. An angiotensin receptor blockade maintains blood pressure-lowering efficacy at 3400 m but not at 5400 m.

Published
2014

12. Relation of filaggrin null mutations with atopy in Croatia

Author

Sabolic Pipinic, Ivana, Varnai, Veda Marija, Turk, Rajka, Breljak, Davorka, Kezic, Sanja, Macan, Jelena, Bavbek, S., Bilo, B., and Bogacka, E. et al.

Subjects
body regions, eczema/dermatitis, filaggrin, gene polymorphism, skin prick testing
Abstract

Background: Null mutations in the gene encoding filaggrin (FLG), which result in the loss of filaggrin production and hence disrupt the epidermal barrier function, have been strongly associated with atopic dermatitis and present a predisposing factor in the development of the atopic march. The frequencies of the most common null mutations among the Caucasian population in Western Europe and North America were analyzed in young adult Croatian population, and their relation to skin and respiratory atopic diseases was assessed. Method: FLG null mutations R501X, 2282del4, R2447X and S3247X were genotyped in 423 students (305 females and 118 males, median age 19 years) with defined atopic phenotype (atopic dermatitis, rhinitis and asthma) by means of recorded atopic skin and respiratory symptoms with modified ISAAC questionnaire and positive skin prick testing (SPT) to one or more common inhalatory allergens. Result: We found 11 FLG null mutations carriers, 1/423 (0.2%) heterozygous for R501X and 10/423 (2, 4%) heterozygous for 2282del4. There were no carriers of R2447X and S3247X mutations. In total sample (N=423), atopic dermatitis was present in 12%, rhinitis in 17% and asthma in 7% of subjects. FLG null mutations were not related to any analyzed atopic phenotype. Among 11 FLG null mutations carriers only 3 (27.3%) had atopic dermatitis, but 9 had eczema/dermatitis symptoms regardless of positive SPT. Multiple logistic regression analysis, controlled for gender, family history of skin allergies and positive SPT, confirmed FLG null mutations as an independent risk factor for presence of eczema/dermatitis symptoms (OR 22, 95%CI 4.4-109.4 ; P

Published
2011

Catalog

Books, media, physical & digital resources
See catalog results